Marqueurs moléculaires tissulaires et sanguins.

The severity of pancreatic ductal adenocarcinoma (AP), the few available treatments and the diversity of therapeutic responses highlight the crucial need to find molecular markers aiming to personalize treatments. Recent research has identified promising molecular signatures, based on transcriptomic analyzes and chemotherapy sensitivity testing. Clinical trials are currently evaluating their effectiveness in guiding the treatment of patients with AP. At the same time, the development of non-invasive methods to predict response to treatments, in particular by exploring blood biomarkers, is necessary. These advances offer considerable potential for a more precise and individualized approach to the treatment of this disease. [ABSTRACT FROM AUTHOR]